Document Detail

Cardiovascular safety of cyclo-oxygenase-2 inhibitors.
MedLine Citation:
PMID:  17307095     Owner:  NLM     Status:  MEDLINE    
Susan S Jick; James A Kaye; Hershel Jick
Related Documents :
21138115 - Ann's perfect pitch. interview by elizabeth lynch.
8477705 - Overproduction, purification and characterization of the bacterioferritin of escherichi...
11159545 - Icl670a: a new synthetic oral chelator: evaluation in hypertransfused rats with selecti...
22658675 - Homelessness as culture: how transcultural nursing theory can assist caring for the hom...
7562075 - Teaching ethics to nurses.
17601235 - A framework for providing evidence-based palliative care.
Publication Detail:
Type:  Comment; Letter    
Journal Detail:
Title:  Lancet     Volume:  369     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-19     Completed Date:  2007-03-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  555-6; author reply 556     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclooxygenase Inhibitors / adverse effects*
Diclofenac / adverse effects*
Myocardial Infarction / chemically induced*
Pyridines / adverse effects*
Randomized Controlled Trials as Topic
Sulfones / adverse effects*
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Pyridines; 0/Sulfones; 15307-86-5/Diclofenac; 202409-33-4/etoricoxib
Comment On:
Lancet. 2006 Nov 18;368(9549):1771-81   [PMID:  17113426 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Revision in autologous breast reconstruction: principles and approach.
Next Document:  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup ...